Table 3.
Clinical and Demographic Factors Associated With Completing Treatment Among Patients Started on Treatment for LTBI
| Clinical and Demographic Characteristics | aOR (95% CI)a | P |
|---|---|---|
| Age > 65 | ||
| No | Ref | |
| Yes | 0.66 (.36, 1.23) | .189 |
| Gender | ||
| Male | Ref | |
| Female | 0.99 (.72, 1.34) | .929 |
| Race | ||
| White | Ref | |
| Unknown/other | 1.29 (.63, 2.66) | .485 |
| Native American | 1.18 (.10, 13.75) | .892 |
| Asian | 1.27 (.73, 2.20) | .402 |
| Black | 0.75 (.46, 1.22) | .249 |
| Native Hawaiian/Pacific Islander | 6.75 (1.59, 28.64) | .010 |
| Hispanic/Latino | ||
| No | Ref | |
| Yes | 0.49 (0.28, 0.86) | .012 |
| Unknown | 0.80 (0.38, 1.68) | .551 |
| Homeless | ||
| No | Ref | |
| Yes | 0.11 (.03, .40) | .001 |
| Evaluated for employment or administrative reasonsb | ||
| No | Ref | |
| Yes | 0.83 (.44, 1.59) | .583 |
| Evaluated for contact investigation | ||
| No | Ref | |
| Yes | 0.92 (.60, 1.42) | .708 |
| Birth country | ||
| Non-USB | Ref | |
| US-born | 0.74 (0.45, 1.23) | .245 |
| Discordant LTBI testing results | ||
| No | Ref | |
| Yes | 1.86 (0.77, 4.50) | .171 |
| Treatment regimen | ||
| INH (6H/9H) | Ref | |
| INH + Rifampin (3HR) | 1.27 (.57, 2.81) | .560 |
| INH + Rifapentine (3HP) | 3.39 (1.85, 6.19) | <.001 |
| Rifampin (4R) | 1.38 (.91, 2.09) | .132 |
| Other/unknown | 1.62 (.15, 17.74) | .694 |
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; INH, isoniazid; LTBI, latent tuberculosis infection; Ref, reference; USB, US-born.
a
Results from a generalized linear mixed-effect multivariable model (logit link and binomial distribution), with random effects incorporated for study site (Supplementary Figure 4).
b
Includes all people with an evaluation for purposes of employment or student clearance.